Transcriptional modulation of the PI3K/AKT/mTOR signaling pathway mediated by HPV16 E5, E6, and E7 oncogene expression in breast cancer

Abstract

Aim: Breast cancer is the most prevalent malignant tumor among women. Human papillomavirus (HPV) has been detected in breast tumors since the 1990s, and beyond its oncogenic potential, therapy resistance driven by viral immune evasion in non-anogenital tumors, such as oropharyngeal cancers, highlights the need to investigate viral activity in breast tissues. Among high-risk HPV types, HPV16 is one of the most prevalent and exhibits the highest carcinogenic potential. Therefore, this study aimed to evaluate the expression of HPV16 oncogenesE5, E6, and E7 in breast tumors, as well as the modulation of the PI3K/AKT/mTOR signaling pathway associated with viral activity.

Methods: A total of 92 breast cancer patients were included after Ethics Committee approval. Clinical data were obtained from medical records. RNA was extracted from formalin-fixed, paraffin-embedded tissues and reverse-transcribed into cDNA. Transcripts of HPV oncogenes E5, E6, and E7), components of the PI3K/AKT/mTOR pathway, and regulatory genes EGFR and PTEN) were quantified by RT-qPCR. Gene expression levels were calculated using the ΔCt method.

Results: Forty-eight samples met RNA quality criteria and were included in the expression analysis. Among these, 77.08% showed expression of at least one viral oncogene, with E5 being the most frequently expressed. The PI3K/AKT/mTOR pathway was modulated in HPV-positive samples, with increased PI3K expression and decreased mTOR expression. Notably, the high expression of E5-associated with immune evasion-combined with reduced mTOR expression suggests that HPV16 status may influence therapeutic response in breast cancer patients.

Conclusions: These findings reinforce the importance of further studies investigating HPV activity in breast tumors to better understand its biological and clinical impact.

Keywords

human papillomavirus / breast cancer carcinogenesis / PI3K/AKT/mTOR pathway

References

[1] Sharma P, Khan MA, Najmi AK, Chaturvedi S, Akhtar M. Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway. Med Oncol. 2022; 39: 248.

[2] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229-63.

[3] Roheel A, Khan A, Anwar F, Akbar Z, Akhtar MF, Imran Khan M, et al. Global epidemiology of breast cancer based on risk factors: a systematic review. Front Oncol. 2023; 13: 1240098.

[4] Shimizu A, Yamaguchi R, Kuriyama Y. Recent advances in cutaneous HPV infection. J Dermatol. 2023; 50: 290-8.

[5] Fonsêca TC, Jural LA, Marañón-Vásquez GA, Magno MB, Roza ALOC, Ferreira DMTP, et al. Global prevalence of human papillomavirus-related oral and oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Clin Oral Investig. 2023; 28: 62.

[6] Iraqui A, Safia A, Mahameed M, Abd Elhadi U, Merchavy S. Global Prevalence and Modifiers of Human Papillomavirus Positivity in Oral Cavity Cancer: A Systematic Review and Meta-Analysis of Prevalence (1995-2024). Cancers (Basel). 2025; 17: 2870.

[7] Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014; 15: 1319-31.

[8] Su P, Ma J, Yu L, Tang S, Sun P. Clinical significance of extended high-risk human papillomavirus genotyping and viral load in cervical cancer and precancerous lesions. Gynecol Obste Cl Med. 2023; 3: 22-9.

[9] Di Lonardo A, Venuti A, Marcante ML. Human papillomavirus in breast cancer. Breast Cancer Res Treat. 1992; 21: 95-100.

[10] Purrahman D, Avarvand AY, Paradowska-Gorycka A, Saki N, Karimpourian H, Jodat H, et al. Association of human papillomavirus with breast cancer: a new perspective on an old debate. Future Oncol. 2022; 18: 2483-94.

[11] Koishybayeva D, Balmagambetova S, Zhakiev B, Koishybayev A, Mussin NM, Sakhanova S, et al. The oncogenic role of human papillomavirus in breast cancer: a comprehensive systematic review and meta-analysis. Front Microbiol. 2025; 16: 1712118.

[12] Liu ZY, Chen R. HPV, APOBEC3B, and the origins of breast cancer: a narrative review and perspectives on novel mechanisms. Front Oncol. 2026; 15: 1737189.

[13] Sakhi Z, Tadlaoui KA, Ennaji Y, Benhessou M, Ennaji MM. Prevalence and Genotypic Distribution of Human Papillomavirus and its Potential Implications in Invasive Breast Cancer: A Molecular Study. Indian J Gynecol Oncol. 2025; 23: 90.

[14] El-Sheikh N, Mousa NO, Tawfeik AM, Saleh AM, Elshikh I, Deyab M, et al. Assessment of Human Papillomavirus Infection and Risk Factors in Egyptian Women With Breast Cancer. Breast Cancer (Auckl). 2021; 15: 1178223421996279.

[15] Maldonado-Rodríguez E, Hernández-Barrales M, Reyes-López A, Godina-González S, Gallegos-Flores PI, Esparza-Ibarra EL, et al. Presence of Human Papillomavirus DNA in Malignant Neoplasia and Non-Malignant Breast Disease. Curr Issues Mol Biol. 2022; 44: 3648-65.

[16] Nascimento KCG, São Marcos BF, Fontes PHB, Isídio BEO, Leão SL, da Silva GRP, et al. HPV Detection in Breast Tumors and Associated Risk Factors in Northeastern Brazil. Cells. 2024; 13: 1132.

[17] Zhao G, Chang J, Wei K. Correlation between breast cancer and human papillomavirus (HPV) infection. Heliyon. 2024; 10: e37027.

[18] Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P. Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct Target Ther. 2025; 10: 44.

[19] Blanco R, Carrillo-Beltrán D, Muñoz JP, Corvalán AH, Calaf GM, Aguayo F. Human Papillomavirus in Breast Carcinogenesis: A Passenger, a Cofactor, or a Causal Agent? Biology (Basel). 2021; 10: 804.

[20] Janecka-Widła A, Majchrzyk K, Mucha-Małecka A, Biesaga B. EGFR/PI3K/Akt/mTOR pathway in head and neck squamous cell carcinoma patients with different HPV status. Pol J Pathol. 2021; 72: 296-314.

[21] Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17: 53.

[22] Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem. 2020; 20: 815-34.

[23] Tito C, Masciarelli S, Colotti G, Fazi F. EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci. 2025; 32: 24.

[24] Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, et al. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. Cancer Treat Rev. 2018; 62: 1-8.

[25] Medić-Milijić N, Jovanić I, Nedeljković M, Marković I, Spurnić I, Milovanović Z, et al. Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients. Life (Basel). 2024; 14: 682.

[26] Cerma K, Piacentini F, Moscetti L, Barbolini M, Canino F, Tornincasa A, et al. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. Biomedicines. 2023; 11: 109.

[27] Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, et al. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep. 2020; 10: 21762.

[28] Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, et al. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. Clin Cancer Res. 2019; 25: 3374-83.

[29] Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther. 2013; 12: 1665-75.

[30] Garg P, Ramisetty S, Nair M, Kulkarni P, Horne D, Salgia R, et al. Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy. Biochem Pharmacol. 2025; 236: 116850.

[31] Korenková V, Scott J, Novosadová V, Jindřichová M, Langerová L, Švec D, et al. Pre-amplification in the context of high-throughput qPCR gene expression experiment. BMC Mol Biol. 2015; 16: 5.

[32] Vermeulen J, Derveaux S, Lefever S, De Smet E, De Preter K, Yigit N, et al. RNA pre-amplification enables large-scale RT-qPCR gene-expression studies on limiting sample amounts. BMC Res Notes. 2009; 2: 235.

[33] Bustin SA, Wittwer CT. MIQE: A Step Toward More Robust and Reproducible Quantitative PCR. Clin Chem. 2017; 63: 1537-8.

[34] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-8.

[35] Rousseeuw PJ. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math. 1987; 20: 53-65.

[36] Bruyere D, Roncarati P, Lebeau A, Lerho T, Poulain F, Hendrick E, et al. Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. Theranostics. 2023; 13: 1130-49.

[37] Meng Q, Zhang Y, Sun H, Yang X, Hao S, Liu B, et al. Human papillomavirus-16 E6 activates the pentose phosphate pathway to promote cervical cancer cell proliferation by inhibiting G6PD lactylation. Redox Biol. 2024; 71: 103108.

[38] Decruyenaere P, Verniers K, Poma-Soto F, Van Dorpe J, Offner F, Vandesompele J. RNA Extraction Method Impacts Quality Metrics and Sequencing Results in Formalin-Fixed, Paraffin-Embedded Tissue Samples. Lab Invest. 2023; 103: 100027.

[39] Ondracek RP, Chen J, Marosy B, Szewczyk S, Medico L, Mohan AS, et al. Results and lessons from dual extraction of DNA and RNA from formalin-fixed paraffin-embedded breast tumor tissues for a large Cancer epidemiologic study. BMC Genomics. 2022; 23: 614.

[40] Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, et al. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Mol Diagn Ther. 2021; 25: 409-24.

[41] Höller A, Nguyen-Sträuli BD, Frauchiger-Heuer H, Ring A. “ Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”. Breast Cancer (Dove Med Press). 2023; 15: 525-40.

[42] Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014; 5: 412-24.

[43] Ayres ARG, Silva GAE. Prevalência de infecção do colo do útero pelo HPV no Brasil: revisão sistemática. Rev Saúde Pública. 2010; 44: 963-74. Portuguese.

[44] Serra ACS, da Silva ANMR, Silva LFA, de Almeida NCC, da Cruz Coelho E, Almeida LWC, et al. CIRCULATING GENOTYPES OF HUMAN PAPILLOMAVIRUS (HPV) IN BRAZIL: A SYSTEMATIC REVIEW OF THE LITERATURE. Braz J Infect Dis. 2026; 30: 105477.

[45] Richter K, Becker P, Horton A, Dreyer G. Age-specific prevalence of cervical human papillomavirus infection and cytological abnormalities in women in Gauteng Province, South Africa. S Afr Med J. 2013; 103: 313-7.

[46] Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, et al. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2017; 140: 2192-200.

[47] Belachew EB, Desta AF, Mulu A, Deneke DB, Tefera DA, Alemu A, et al. High rate of high-risk human papillomavirus among benign and breast cancer patients in Ethiopia. PLoS One. 2024; 19: e0298583.

[48] Islam MS, Chakraborty B, Panda CK. Human papilloma virus (HPV) profiles in breast cancer: future management. Ann Transl Med. 2020; 8: 650.

[49] Khasawneh AI, Himsawi N, Sammour A, Al Shboul S, Alorjani M, Al-Momani H, et al. Association of Human Papilloma Virus, Cytomegalovirus, and Epstein-Barr Virus with Breast Cancer in Jordanian Women. Medicina (Kaunas). 2024; 60: 699.

[50] Chen B, Zhao L, Yang R, Xu T. Advances in molecular mechanism of HPV16 E5 oncoprotein carcinogenesis. Arch Biochem Biophys. 2023; 745: 109716.

[51] Haręża DA, Wilczyński JR, Paradowska E. Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins. Int J Mol Sci. 2022; 23: 1818.

[52] Hochmann J, Parietti F, Martínez J, Lopez AC, Carreño M, Quijano C, et al. Human papillomavirus type 18 E5 oncoprotein cooperates with E6 and E7 in promoting cell viability and invasion and in modulating the cellular redox state. Mem Inst Oswaldo Cruz. 2020; 115: e190405.

[53] Ren S, Gaykalova DA, Guo T, Favorov AV, Fertig EJ, Tamayo P, et al. HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers. Oncogene. 2020; 39: 6327- 39.

[54] da Silva-Júnior AHP, de Oliveira Silva RC, Gurgel APAD, Barros-Júnior MR, Nascimento KCG, Santos DL, et al. Identification and Functional Implications of the E5 Oncogene Polymorphisms of Human Papillomavirus Type 16. Trop Med Infect Dis. 2024; 9: 140.

[55] Ilahi NE, Bhatti A. Impact of HPV E5 on viral life cycle via EGFR signaling. Microb Pathog. 2020; 139: 103923.

[56] Scott ML, Woodby BL, Ulicny J, Raikhy G, Orr AW, Songock WK, et al. Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance. J Virol. 2020; 94: e01582-19.

[57] Pérez-Morales AC, Maldonado-Gama M, Méndez-Armenta M, Esquivel-Guadarrama F, Gutierrez-Xicotencatl L. Role of E5 from HPV16 in the Evasion of the Immune Response. Int J Mol Sci. 2026; 27: 1985.

[58] Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, et al. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. Cancer Res. 2020; 80: 732-46.

[59] Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, et al. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024; 23: 266.

[60] Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023; 24: 6834.

[61] Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017; 13: 1387-97.

[62] Ganesan K, Xu C, Wu J, Du B, Liu Q, Sui Y, et al. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway. Sci China Life Sci. 2024; 67: 1849-66.

[63] Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press). 2015; 7: 111-23.

[64] Park JY, Kang SE, Ahn KS, Um JY, Yang WM, Yun M, et al. Inhibition of the PI3K-AKT-mTOR pathway suppresses the adipocyte-mediated proliferation and migration of breast cancer cells. J Cancer. 2020; 11: 2552-9.

[65] Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer. Int J Mol Sci. 2021; 22: 11088.

[66] Tufail M, Hu JJ, Liang J, He CY, Wan WD, Huang YQ, et al. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway. J Transl Med. 2024; 22: 15.

[67] Verret B, Cortes J, Bachelot T, Andre F, Arnedos M. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019; 30 Suppl 10: x12-20.

[68] Liu J, Huang B, Xiu Z, Zhou Z, Liu J, Li X, et al. PI3K/Akt/HIF-1α signaling pathway mediates HPV-16 oncoprotein-induced expression of EMT-related transcription factors in non-small cell lung cancer cells. J Cancer. 2018; 9: 3456-66.

[69] Contreras-Paredes A, De la Cruz-Hernández E, Martínez-Ramírez I, Dueñas-González A, Lizano M. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology. 2009; 383: 78-85.

[70] Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96: 857-68.

[71] Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, et al. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature. 2014; 508: 541-5.

[72] Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016; 35: 515-24.

[73] Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR, et al. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? Front Pharmacol. 2021; 12: 662232.

[74] Morales-Garcia V, Contreras-Paredes A, Martinez-Abundis E, Gomez-Crisostomo NP, Lizano M, Hernandez-Landero F, et al. The high-risk HPV E6 proteins modify the activity of the eIF4E protein via the MEK/ERK and AKT/PKB pathways. FEBS Open Bio. 2020; 10: 2541-52.

[75] Chang X, Tian C, Jia Y, Cai Y, Yan P. MLXIPL promotes the migration, invasion, and glycolysis of hepatocellular carcinoma cells by phosphorylation of mTOR. BMC Cancer. 2023; 23: 176.

[76] Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017; 168: 960-76.

[77] Li Q, Li Z, Luo T, Shi H. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Mol Biomed. 2022; 3: 47.

[78] Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023; 8: 375.

[79] Xie S, Chen M, Yan B, He X, Chen X, Li D. Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. PLoS One. 2014; 9: e94496.

[80] Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci. 2020; 22: 173.

[81] Aguayo F, Perez-Dominguez F, Osorio JC, Oliva C, Calaf GM. PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications. Biology (Basel). 2023; 12: 672.

[82] Callejas-Valera JL, Iglesias-Bartolome R, Amornphimoltham P, Palacios-Garcia J, Martin D, Califano JA, et al. mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model. Carcinogenesis. 2016; 37: 1014-25.

[83] Spangle JM, Münger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol. 2010; 84: 9398-407.

[84] Bossler F, Kuhn BJ, Günther T, Kraemer SJ, Khalkar P, Adrian S, et al. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling. mBio. 2019; 10: e02323-18.

[85] Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366: 520-9.

[86] Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, et al.; I-SPY 2 Consortium. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020; 38: 1059-69.

[87] Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, et al. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. 2019; 30: 774-80.

[88] Lou H, Langan D, Syracuse N, Murphy EA, Kim S, Robinson E, et al. A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy. medRxiv [Preprint]. 2026 [cited 2026 Feb 5]. Available from: https://doi.org/10.64898/2026.01.21.26344562

[89] Nathan CO, Hayes DN, Karrison T, Harismendy O, Flores JM, Moore-Medlin T, et al. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022; 28: 5040-8.

[90] Lu Z, Lee J, Liu R, Li J, Wang Y, Tan L, et al. EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mendeley Data; 2018.

[91] Chai C, Wu HH, Abuetabh Y, Sergi C, Leng R. Regulation of the tumor suppressor PTEN in triple-negative breast cancer. Cancer Lett. 2022; 527: 41-8.

[92] Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014; 27: 1212-22.

[93] Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, Blair GE. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene. 2008; 27: 1794-9.

[94] Skelin J, Sabol I, Tomaić V. Do or Die: HPV E5, E6 and E7 in Cell Death Evasion. Pathogens. 2022; 11: 1027.

[95] São Marcos BF, Santos DLD, Sousa GF, Cruz LCO, Barros BRDS, de Sena MGAM, et al. Immune Response Modulation by HPV16 Oncoproteins in Lung Cancer: Insights from Clinical and In Vitro Investigations. Viruses. 2024; 16: 1731.

[96] Masson GR, Williams RL. Structural Mechanisms of PTEN Regulation. Cold Spring Harb Perspect Med. 2020; 10: a036152.

[97] Tang JY, Li DY, He L, Qiu XS, Wang EH, Wu GP. HPV 16 E6/E7 Promote the Glucose Uptake of GLUT1 in Lung Cancer Through Downregulation of TXNIP Due to Inhibition of PTEN Phosphorylation. Front Oncol. 2020; 10: 559543.

[98] DE Jesus Oliveira Kato V, DE Abreu MC, DE Brito Kato AM, DE Souza LL, Pontes FSC, DE Castro Sant’anna C, et al. Significance of P16INK4A Expression and PTEN Loss of Heterozygosity in Human Papilloma Virus-related Oral Squamous Cell Carcinoma. Anticancer Res. 2020; 40: 6355-66.

[99] Naderi Z, Hamidzade M, Yari AH, Safarzadeh H, Nahand JS, Rezaei M, et al. Decoding the relationships among miRNA, HPV infection, and tumor suppressor gene expression in breast cancer patients. Sci Rep. 2025; 15: 44247.

[100] Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition. Neoplasia. 2013; 15: 620-30.

[101] Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer. 2020; 122: 1732-43.

[102] Morgan EL, Macdonald A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NFκB-IL-6 signalling axis. PLoS Pathog. 2019; 15: e1007835.

[103] Zhang L, Wu J, Ling MT, Zhao L, Zhao KN. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015; 14: 87.